Researchers just discovered that terbinafine (the athlete’s foot medication) and miglustat (a rare disease drug) can extend mouse lifespan by roughly 15% — and they work through a mechanism we’ve seen before in longevity research.
Both drugs trigger controlled mitochondrial stress, forcing cells to activate their internal repair systems. Think of it like hormesis — the biological principle where a small amount of stress makes you stronger. These medications essentially make mitochondria work a bit harder, which paradoxically makes them more resilient over time.
The mitochondrial stress response is fascinating because it’s conserved across species. When your cellular powerhouses get mildly stressed, they ramp up quality control mechanisms, clear out damaged components, and become more efficient. It’s the same pathway activated by intermittent fasting, cold exposure, and exercise.
What makes this study particularly interesting is the drug repurposing angle. Terbinafine has been used safely for decades to treat fungal infections. Miglustat treats Gaucher disease. Both have known safety profiles in humans, which could accelerate any potential longevity applications.
The researchers found that both drugs activated AMPK and mitochondrial biogenesis pathways — the same molecular targets that rapamycin and metformin hit. The mice showed improved metabolic markers and delayed age-related decline across multiple tissue types.
But here’s the reality check: this is early-stage research in laboratory mice. The doses used were therapeutic levels for the drugs’ existing indications, but translating effective longevity doses to humans remains guesswork.
The Protocol says: Fascinating mechanism, proven safety profile, but way too early for human application. The mitochondrial stress angle is scientifically sound, but we need human biomarker studies before anyone considers off-label use.
This could be the beginning of a new category of longevity interventions hiding in plain sight on pharmacy shelves.
Study published in Aging Cell examining repurposed antifungal and metabolic drugs as potential lifespan modulators through mitochondrial pathways.